We are live on !
Find out more
Creative Planning Portfolio holdings
AUM
$171B
Turnover
10.62%
1-Year Est. Return
24.68%
This Fund
S&P 500
This Quarter Est. Return
+14.14%
1 Year Est. Return
+24.68%
3 Year Est. Return
+62.17%
5 Year Est. Return
+55.89%
10 Year Est. Return
+171.9%
AUM
$171B
AUM Growth
+$23.7B
(+16%)
Cap. Flow
+$6.93B
Cap. Flow % of AUM
Cap. Flow %
4.05%
Top 10 Holdings %
Top 10 Hldgs %
41.66%
Holding
4,427
New
337
Increased
2,605
Reduced
1,239
Closed
133
Avg Time Held
Equity + Options
4.2
years
Top 10 Avg Time Held
Equity + Options
1.7
years
Top 20 Avg Time Held
Equity + Options
4.3
years
Avg Time Held Equity only
4.3
years
Top 10 Avg Time Held Equity only
1.7
years
Top 20 Avg Time Held Equity only
4.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total Bond Market
BND
|
+$682M |
| 2 |
State Street SPDR Portfolio Developed World ex-US ETF
SPDW
|
+$526M |
| 3 |
Vanguard Short-Term Bond ETF
BSV
|
+$504M |
| 4 |
iShares Core S&P 500 ETF
IVV
|
+$431M |
| 5 |
State Street SPDR Portfolio S&P 400 Mid Cap ETF
SPMD
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$239M |
| 2 |
Vanguard Morningstar Large-Cap ETF
VV
|
+$74.4M |
| 3 |
Vanguard Morningstar Mid-Cap ETF
VO
|
+$41.1M |
| 4 |
Honeywell
HON
|
+$39.3M |
| 5 |
iShares Core US Aggregate Bond ETF
AGG
|
+$38.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 73.8% |
| 2 | Technology | 9.57% |
| 3 | Financials | 3.79% |
| 4 | Industrials | 2.49% |
| 5 | Healthcare | 2.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2726
American Assets Trust
AAT
$1.31B
| $904K | ﹤0.01% |
36,617
+9,458
| +35% | +$207K |
2025 Q2
4 quarters
|
|
2727
Heartland Express
HTLD
$787M
| $904K | ﹤0.01% |
59,364
-150
| -0.3% | -$2.03K |
2024 Q2
8 quarters
|
|
2728
Calvert US Mid-Cap Core Responsible Index ETF
CVMC
$120M
| $900K | ﹤0.01% |
11,826
| – | – |
2024 Q4
6 quarters
|
|
2729
Capital City Bank Group
CCBG
$865M
| $900K | ﹤0.01% |
18,207
+596
| +3% | +$27.6K |
2025 Q3
3 quarters
|
|
2730
Invesco NASDAQ Next Gen 100 ETF
QQQJ
$1.17B
| $900K | ﹤0.01% |
19,801
+5,844
| +42% | +$246K |
2024 Q1
9 quarters
|
|
2731
iShares S&P India Nifty 50 Index Fund
INDY
$501M
| $899K | ﹤0.01% |
20,680
-4,209
| -17% | -$182K |
2022 Q1
17 quarters
|
|
2732
Clarivate
CLVT
$1.2B
| $898K | ﹤0.01% |
415,956
-223,648
| -35% | -$547K |
2024 Q3
7 quarters
|
|
2733
WEX
WEX
$6.73B
| $897K | ﹤0.01% |
6,356
-14,264
| -69% | -$2.11M |
2022 Q4
14 quarters
|
|
2734
AMC Global Media
AMCX
$379M
| $896K | ﹤0.01% |
+89,793
| New | +$796K |
2026 Q2
0 quarters
|
|
2735
Innovator US Equity Power Buffer ETF July
PJUL
$1.3B
| $895K | ﹤0.01% |
18,345
+20
| +0.1% | +$961 |
2026 Q1
1 quarter
|
|
2736
TCW Transform 500 ETF
VOTE
$1.12B
| $893K | ﹤0.01% |
10,126
-163
| -2% | -$13.9K |
2021 Q4
18 quarters
|
|
2737
Fidelity MSCI Energy Index ETF
FENY
$2.35B
| $891K | ﹤0.01% |
30,137
-237
| -0.8% | -$7.55K |
2024 Q1
9 quarters
|
|
2738
First Trust NYSE Arca Biotechnology Index Fund
FBT
$2.96B
| $891K | ﹤0.01% |
3,593
-586
| -14% | -$126K |
2022 Q1
17 quarters
|
|
2739
Invesco BulletShares 2029 Corporate Bond ETF
BSCT
$3.06B
| $890K | ﹤0.01% |
47,936
-12,586
| -21% | -$235K |
2024 Q3
7 quarters
|
|
2740
Allogene Therapeutics
ALLO
$432M
| $887K | ﹤0.01% |
426,437
+61,628
| +17% | +$135K |
2023 Q3
11 quarters
|
|
2741
Harrow
HROW
$1.07B
| $886K | ﹤0.01% |
20,863
-1,410
| -6% | -$52.4K |
2023 Q4
10 quarters
|
|
2742
Rigel Pharmaceuticals
RIGL
$899M
| $886K | ﹤0.01% |
22,637
+8,907
| +65% | +$275K |
2025 Q3
3 quarters
|
|
2743
State Street SPDR MSCI Emerging Markets Fossil Fuel Reserves Free ETF
EEMX
$171M
| $886K | ﹤0.01% |
16,353
+3,485
| +27% | +$178K |
2022 Q4
14 quarters
|
|
2744
Hudbay
HBM
$9.8B
| $885K | ﹤0.01% |
37,489
+3,986
| +12% | +$101K |
2018 Q3
31 quarters
|
|
2745
Aurinia Pharmaceuticals
AUPH
$2.24B
| $885K | ﹤0.01% |
52,157
+13,513
| +35% | +$216K |
2024 Q2
8 quarters
|
|
2746
Blue Bird Corp
BLBD
$1.97B
| $882K | ﹤0.01% |
11,164
+3,600
| +48% | +$244K |
2025 Q3
3 quarters
|
|
2747
Procept Biorobotics
PRCT
$1.14B
| $880K | ﹤0.01% |
38,992
-446
| -1% | -$11.2K |
2024 Q2
8 quarters
|
|
2748
Intellia Therapeutics
NTLA
$1.57B
| $880K | ﹤0.01% |
52,020
-390
| -0.7% | -$5.46K |
2023 Q3
11 quarters
|
|
2749
Arcutis Biotherapeutics
ARQT
$3.92B
| $880K | ﹤0.01% |
33,565
+3,914
| +13% | +$91.2K |
2024 Q3
7 quarters
|
|
2750
Olema Pharmaceuticals
OLMA
$561M
| $879K | ﹤0.01% |
70,263
-1,971
| -3% | -$26.4K |
2025 Q2
4 quarters
|
|
Similar funds
Creative Planning's Q2 2026 Portfolio in Review
As of Q2 2026, Creative Planning held 4,427 positions worth $171B, up 16% from $147B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Creative Planning deployed $6.93B of net new capital in Q2 2026, opening 337 new positions and adding to 2,605 existing holdings. Its largest new stake was Honeywell Aerospace: 169,880 shares worth $37.6M.
By sector, the portfolio is most concentrated in Miscellaneous at 74% of assets, down from 76% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Vanguard FTSE Developed Markets ETF, an estimated $239M trimmed.
- Creative Planning's largest Q2 2026 buy was Honeywell Aerospace: 169,880 shares worth $37.6M.
- Creative Planning added most to Vanguard Total Bond Market in Q2 2026, an estimated $682M increase.
- Creative Planning's biggest Q2 2026 reduction was Vanguard FTSE Developed Markets ETF, cutting an estimated $239M.
- Creative Planning fully exited Hologic in Q2 2026, selling an estimated $8.29M.
- Creative Planning's ten largest holdings make up 42% of its $171B portfolio in Q2 2026.
- Creative Planning opened 337 new positions and closed 133 in Q2 2026.
- Creative Planning's portfolio value rose 16% quarter-over-quarter to $171B.
Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.